Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ)
CNY 32.71
(-0.58%)
CNY 32.71
(-0.58%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 9.39 Billion CNY | -3.67% |
| 2022 | 9.75 Billion CNY | 5.53% |
| 2021 | 9.24 Billion CNY | 33.61% |
| 2020 | 6.91 Billion CNY | -10.54% |
| 2019 | 7.73 Billion CNY | -2.17% |
| 2018 | 7.9 Billion CNY | 15.16% |
| 2017 | 6.86 Billion CNY | 5.05% |
| 2016 | 6.53 Billion CNY | 21.3% |
| 2015 | 5.38 Billion CNY | 16.7% |
| 2014 | 4.61 Billion CNY | 26.7% |
| 2013 | 3.64 Billion CNY | 22.23% |
| 2012 | 2.98 Billion CNY | 21.9% |
| 2011 | 2.44 Billion CNY | 12.43% |
| 2010 | 2.17 Billion CNY | 22.74% |
| 2009 | 1.77 Billion CNY | 333.66% |
| 2008 | 408.6 Million CNY | 59.65% |
| 2007 | 255.94 Million CNY | 61.31% |
| 2006 | 158.66 Million CNY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 9.61 Billion CNY | 2.27% |
| 2024 Q2 | 9.63 Billion CNY | 0.31% |
| 2024 Q3 | 10.23 Billion CNY | 6.15% |
| 2023 Q4 | 9.39 Billion CNY | -0.35% |
| 2023 Q3 | 9.42 Billion CNY | -0.76% |
| 2023 Q2 | 9.5 Billion CNY | -1.74% |
| 2023 FY | 9.39 Billion CNY | -3.67% |
| 2023 Q1 | 9.67 Billion CNY | -0.87% |
| 2022 Q1 | 9.69 Billion CNY | 4.91% |
| 2022 FY | 9.75 Billion CNY | 5.53% |
| 2022 Q4 | 9.75 Billion CNY | 2.4% |
| 2022 Q3 | 9.52 Billion CNY | 0.06% |
| 2022 Q2 | 9.52 Billion CNY | -1.82% |
| 2021 Q1 | 6.94 Billion CNY | 0.43% |
| 2021 FY | 9.24 Billion CNY | 33.61% |
| 2021 Q4 | 9.24 Billion CNY | -0.09% |
| 2021 Q3 | 9.25 Billion CNY | -1.09% |
| 2021 Q2 | 9.35 Billion CNY | 34.62% |
| 2020 Q4 | 6.91 Billion CNY | -3.04% |
| 2020 Q1 | 8.02 Billion CNY | 3.78% |
| 2020 FY | 6.91 Billion CNY | -10.54% |
| 2020 Q3 | 7.13 Billion CNY | -2.02% |
| 2020 Q2 | 7.28 Billion CNY | -9.26% |
| 2019 Q2 | 7.67 Billion CNY | -5.25% |
| 2019 Q1 | 8.1 Billion CNY | 2.51% |
| 2019 FY | 7.73 Billion CNY | -2.17% |
| 2019 Q4 | 7.73 Billion CNY | -1.4% |
| 2019 Q3 | 7.84 Billion CNY | 2.16% |
| 2018 Q4 | 7.9 Billion CNY | 4.33% |
| 2018 Q3 | 7.57 Billion CNY | 13.77% |
| 2018 FY | 7.9 Billion CNY | 15.16% |
| 2018 Q2 | 6.65 Billion CNY | -7.11% |
| 2018 Q1 | 7.16 Billion CNY | 4.44% |
| 2017 Q3 | 6.51 Billion CNY | 6.71% |
| 2017 Q2 | 6.1 Billion CNY | -10.78% |
| 2017 FY | 6.86 Billion CNY | 5.05% |
| 2017 Q4 | 6.86 Billion CNY | 5.35% |
| 2017 Q1 | 6.84 Billion CNY | 4.73% |
| 2016 FY | 6.53 Billion CNY | 21.3% |
| 2016 Q4 | 6.53 Billion CNY | 5.48% |
| 2016 Q1 | 5.75 Billion CNY | 6.79% |
| 2016 Q3 | 6.19 Billion CNY | 6.97% |
| 2016 Q2 | 5.79 Billion CNY | 0.67% |
| 2015 Q4 | 5.38 Billion CNY | 3.81% |
| 2015 FY | 5.38 Billion CNY | 16.7% |
| 2015 Q3 | 5.18 Billion CNY | 14.25% |
| 2015 Q1 | 4.71 Billion CNY | 2.1% |
| 2015 Q2 | 4.54 Billion CNY | -3.63% |
| 2014 Q4 | 4.61 Billion CNY | 18.22% |
| 2014 Q1 | 3.85 Billion CNY | 5.82% |
| 2014 Q3 | 3.9 Billion CNY | -1.06% |
| 2014 FY | 4.61 Billion CNY | 26.7% |
| 2014 Q2 | 3.94 Billion CNY | 2.37% |
| 2013 Q1 | 3.16 Billion CNY | 6.21% |
| 2013 FY | 3.64 Billion CNY | 22.23% |
| 2013 Q4 | 3.64 Billion CNY | 9.6% |
| 2013 Q3 | 3.32 Billion CNY | 10.44% |
| 2013 Q2 | 3 Billion CNY | -4.93% |
| 2012 Q4 | 2.98 Billion CNY | 6.41% |
| 2012 FY | 2.98 Billion CNY | 21.9% |
| 2012 Q1 | 2.6 Billion CNY | 6.68% |
| 2012 Q2 | 2.61 Billion CNY | 0.41% |
| 2012 Q3 | 2.8 Billion CNY | 6.95% |
| 2011 Q1 | 2.27 Billion CNY | 4.52% |
| 2011 Q3 | 2.37 Billion CNY | 3.09% |
| 2011 FY | 2.44 Billion CNY | 12.43% |
| 2011 Q4 | 2.44 Billion CNY | 2.74% |
| 2011 Q2 | 2.3 Billion CNY | 1.56% |
| 2010 Q2 | 1.98 Billion CNY | 4.7% |
| 2010 Q1 | 1.89 Billion CNY | 6.88% |
| 2010 Q4 | 2.17 Billion CNY | 2.03% |
| 2010 FY | 2.17 Billion CNY | 22.74% |
| 2010 Q3 | 2.13 Billion CNY | 7.49% |
| 2009 Q3 | 1.7 Billion CNY | 216.22% |
| 2009 FY | 1.77 Billion CNY | 333.66% |
| 2009 Q2 | 537.78 Million CNY | 0.0% |
| 2009 Q4 | 1.77 Billion CNY | 4.2% |
| 2008 Q4 | 408.6 Million CNY | 0.0% |
| 2008 FY | 408.6 Million CNY | 59.65% |
| 2007 FY | 255.94 Million CNY | 61.31% |
| 2006 FY | 158.66 Million CNY | 0.0% |